Clinical quality impact: Novo must document how negative trial results change benefit–risk assessments and Go/No-Go decisions.
Regulatory impact: Teams must align ongoing studies, authority communications, and development plans with the latest evidence.
Portfolio impact: Novo needs more viable assets as semaglutide patent expirations approach and Eli Lilly increases competitive pressure.
ZEUS Phase 3 Failure Deepens Novo’s Pipeline Setbacks
Ziltivekimab failed to significantly reduce major adverse cardiovascular events in the Phase 3 ZEUS trial involving patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation. However, Novo will continue two other studies in heart failure and post-heart-attack populations, with results expected in the first half of 2027. Therefore, one failed study has weakened the asset without yet ending its entire development program.
Meanwhile, Novo ended development of monlunabant, the oral cannabinoid receptor blocker it gained through the $1 billion acquisition of Inversago Pharma. Earlier Phase 2a findings showed weight loss but also raised questions about neuropsychiatric tolerability. Unlike ziltivekimab, which still has two active late-stage studies, monlunabant has now left the pipeline.
These outcomes add to pressure from recent CagriSema results and the growing obesity-market competition with Eli Lilly. In response, Doustdar said Novo will accelerate internal research, pursue smaller bolt-on acquisitions, and present more early-stage projects.
Novo Must Decide Which Assets Still Justify Another Trial
The trial results do not demonstrate a quality-system failure. Instead, they test whether Novo can translate disappointing evidence into timely, consistent, and traceable decisions.
The table below converts that governance challenge into immediate actions for regulated teams.
| Role | Main risk | Immediate action | Required evidence | Deadline |
|---|---|---|---|---|
|
Clinical Quality |
Inconsistent decision criteria |
Reassess stage-gate rules |
Approved Go/No-Go framework |
Within 30 days |
|
Regulatory Affairs |
Misaligned commitments |
Map results against authority interactions |
Updated regulatory strategy |
Before the next agency meeting |
|
Safety and PV |
Fragmented benefit–risk interpretation |
Reconcile findings across indications |
Updated benefit–risk assessment |
Before the next safety review |
|
R&D Leadership |
Repeating weak assumptions |
Apply common evidence thresholds |
Portfolio decision record |
Before the next investment cycle |
Decision challenge: After ZEUS failed, should Novo continue the remaining ziltivekimab studies unchanged, redesign them, or stop the program? A defensible decision must consider population differences, serious infection findings, remaining scientific rationale, regulatory feedback, and the value of the evidence still to come.
CagriSema, New Deals and 2027 Data Will Define Novo’s Recovery
The next signals will include Novo’s September early-stage pipeline update, further CagriSema data, and results from the continuing ziltivekimab studies in 2027. These developments will show whether Novo can turn recent failures into faster, evidence-based portfolio decisions.
Pipeline resilience requires disciplined governance, documented risk decisions, and clear accountability. Zamann Pharma Support’s Quality Management System service offers a practical route for strengthening those controls across complex pharmaceutical development programs.
Source: Reuters.Com